Neuroscience 2005 Abstract
| Presentation Number: | 897.6 |
|---|---|
| Abstract Title: | Glucagon-like peptide-1 (7-36) amide (GLP-1) preserves dopamine neurons and motor function in experimental parkinsonism. |
| Authors: |
Greig, N. H.*
; Perry, T.
; Kindy, M. S.1
1Dept. Physiology & Neuroscience, Med. Univ. of South Carolina, Charleston, SC |
| Primary Theme and Topics |
Disorders of the Nervous System - Neurodegenerative and Movement Disorders -- Parkinson's disease: Therapies |
| Secondary Theme and Topics | Disorders of the Nervous System<br />- Neurodegenerative and Movement Disorders<br />-- Parkinson's disease: Other |
| Session: |
897. Parkinson's Disease Models: MPTP II Poster |
| Presentation Time: | Wednesday, November 16, 2005 9:00 AM-10:00 AM |
| Location: | Washington Convention Center - Hall A-C, Board # RR22 |
| Keywords: | PARKINSON, NEUROPEPTIDE, NEURODEGENERATION, NEUROPROTECTION |
GLP-1 is an endogenous insulinotropic peptide that is secreted from the gastrointestinal tract in response to food. It enhances pancreatic islet beta-cell proliferation, glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus. GLP-1 receptors, are coupled to the cyclic AMP second messenger pathway, and are expressed throughout the nervous system of rodents and humans. We previously reported that GLP-1 and long-acting analogues that bind at the GLP-1 receptor (GLP-1R) possess neurotrophic properties, protect neurons against glutamate- and Aβ-induced apoptosis and attenuate cholinergic neuron atrophy in the basal forebrain of the rat following an excitotoxic lesion (TIPS 24:377-83, 2003). We now demonstrate that GLP-1 is highly effective in protecting midbrain dopaminergic neurons and improving behavioral outcome in a mouse model of Parkinson's disease. Mice given intraventricular GLP-1 exhibited improved motor function, reduced damage to nigrostriatal dopaminergic neurons and reduced depletion of dopamine and its metabolites after exposure to the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Together with the neurotrophic effects of these peptides, we suggest that GLP-1 agonists offer significant protection against neuronal insults, which are pertinent to neurodegeneration in both the central and peripheral nervous systems.
Supported by the National Institute on Aging Intramural Research Program.
Supported by the National Institute on Aging Intramural Research Program.
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2005 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2005. Online.
Copyright © 2005-2024 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
